ADARx Pharmaceuticals (NASDAQ:ADRX) Stock Rating Upgraded by Zacks Research

by · The Markets Daily

ADARx Pharmaceuticals (NASDAQ:ADRX – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued on Wednesday, Zacks reports.

A number of other equities analysts also recently commented on ADRX. JPMorgan Chase & Co. initiated coverage on ADARx Pharmaceuticals in a report on Tuesday. They set an “overweight” rating and a $38.00 target price for the company. Wall Street Zen upgraded shares of ADARx Pharmaceuticals to a “hold” rating in a report on Saturday, October 3rd. Morgan Stanley began coverage on shares of ADARx Pharmaceuticals in a research report on Tuesday. They set an “overweight” rating and a $32.00 price objective on the stock. UBS Group began coverage on shares of ADARx Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $35.00 price target for the company. Finally, TD Cowen began coverage on shares of ADARx Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating on the stock. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

View Our Latest Analysis on ADARx Pharmaceuticals

ADARx Pharmaceuticals Trading Up 3.2%

ADRX opened at $17.68 on Wednesday. ADARx Pharmaceuticals has a 12 month low of $16.61 and a 12 month high of $23.21.

Insider Buying and Selling at ADARx Pharmaceuticals

In other news, Director Simeon George purchased 1,600,000 shares of the stock in a transaction dated Monday, September 28th. The shares were purchased at an average cost of $17.00 per share, with a total value of $27,200,000.00. Following the acquisition, the director directly owned 5,554,094 shares of the company’s stock, valued at $94,419,598. This represents a 40.46% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc purchased 1,600,000 shares of the company’s stock in a transaction dated Monday, September 28th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the purchase, the insider owned 5,554,094 shares in the company, valued at approximately $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 3,261,516 shares of company stock worth $55,445,772.

About ADARx Pharmaceuticals

(Get Free Report)

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company’s platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.

ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.

See Also